Prenetics Global (NASDAQ:PRE) Issues Quarterly Earnings Results

Prenetics Global (NASDAQ:PRE) announced its quarterly earnings results on Tuesday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.11, Zacks reports. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 19.46%. The firm had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.02 million.

Here are the key takeaways from Prenetics Global’s conference call:

• Record growth continued: Q2 revenue reached $46.5 million, up 29% sequentially and nearly fourfold year over year, while July revenue climbed to $20.9 million. IM8 reported 65% gross margins and its sixth consecutive record quarter.
• Guidance was raised materially: Full-year 2026 revenue guidance increased to $220 million-$230 million, and the company initiated 2027 guidance of at least $400 million. Management expects to exit 2026 at a revenue run rate above $300 million.
• Customer economics improved with scale: July brought a record 47,373 new customers at a $239 acquisition cost, roughly 21% below the Q2 average, alongside 140,000 active subscribers and approximately 87% recurring revenue. General Catalyst’s $1 billion growth financing is expected to fund about 70% of acquisition marketing.
• Expansion is planned but remains execution-dependent: IM8 expects to launch hydration in Q4 and gummies in early 2027, supported by clinical studies including trials at Mayo Clinic. Management emphasized that these products are not included in current guidance, so their contribution remains uncertain.
• Profitability is still developing: Q2 adjusted EBITDA was negative $19 million and net loss was $9 million, with losses largely driven by increased customer acquisition spending. Although management expects second-half adjusted EBITDA losses to narrow to $8 million-$12 million and adjusted free cash flow to remain positive, these measures depend partly on the General Catalyst financing structure.

Prenetics Global Price Performance

Shares of NASDAQ:PRE opened at $18.76 on Thursday. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63. The business’s 50-day moving average is $19.13 and its 200-day moving average is $18.88. The company has a market capitalization of $316.48 million, a price-to-earnings ratio of -4.51 and a beta of 0.26.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Wall Street Zen lowered Prenetics Global from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Benchmark increased their price target on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Prenetics Global presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Institutional Investors Weigh In On Prenetics Global

A number of hedge funds have recently added to or reduced their stakes in the business. Quadrature Capital Ltd acquired a new position in Prenetics Global in the fourth quarter valued at approximately $468,000. Millennium Management LLC bought a new stake in shares of Prenetics Global in the 4th quarter valued at $810,000. Boothbay Fund Management LLC bought a new stake in shares of Prenetics Global in the 4th quarter valued at $241,000. Jump Financial LLC acquired a new position in shares of Prenetics Global during the 4th quarter valued at $268,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Prenetics Global during the 4th quarter valued at $307,000. 25.01% of the stock is currently owned by institutional investors.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.